TY - JOUR
T1 - Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs
AU - Powell, Michael F.
AU - Eastman, Donna J.
AU - Lim, Amy
AU - Lucas, Catherine
AU - Peterson, Michael
AU - Vennari, Joann
AU - Weissburg, Robert P.
AU - Wrin, Terri
AU - Kensil, Charlotte R.
AU - Newman, Mark J.
AU - Nunberg, Jack
AU - Cleland, Jeffrey L.
AU - Gregory, Tim J.
AU - Berman, Phillip W.
PY - 1995/2
Y1 - 1995/2
N2 - The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.
AB - The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.
UR - http://www.scopus.com/inward/record.url?scp=0029141671&partnerID=8YFLogxK
U2 - 10.1089/aid.1995.11.203
DO - 10.1089/aid.1995.11.203
M3 - Article
C2 - 7742035
AN - SCOPUS:0029141671
SN - 0889-2229
VL - 11
SP - 203
EP - 209
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 2
ER -
